Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 plus etoposide and cisplatin versus placebo plus etoposide and cisplatin as first-line treatment for advanced neuroendocrine carcinoma
CTR20263604Phase 3Active
- Sponsor
- Zelgen
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nilvanstomig in neuroendocrine carcinoma (NEC), sponsored by Zelgen. Started Sep 2026; status: active.
02
Drugs
nilvanstomig
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20263604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263604.